Teladoc Health (NYSE:TDOC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “Teladoc’s shares have outperformed its industry in a year's time. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. It is witnessing growth in its client roster due to the addition of new clients across multiple market segments. Teladoc is witnessing an increase in revenues driven by a rise membership and visits. Its sturdy 2019 guidance should instill investors’ confidence in the stock. However, it has incurred significant losses and has been unable to generate cash from operations. Its struggles may continue in the coming quarters too. Its high debt level caused a spike in interest expenses, which weighs on operating margins.”
A number of other brokerages have also recently issued reports on TDOC. Cantor Fitzgerald restated a “hold” rating and issued a $83.00 price objective on shares of Teladoc Health in a research note on Monday, January 7th. TheStreet upgraded Teladoc Health from a “d+” rating to a “c” rating in a research note on Wednesday, February 20th. SunTrust Banks boosted their price objective on Teladoc Health to $75.00 and gave the company a “positive” rating in a research note on Monday, March 4th. Berenberg Bank started coverage on Teladoc Health in a research note on Thursday, January 31st. They issued a “buy” rating and a $80.00 price objective on the stock. Finally, Robert W. Baird upgraded Teladoc Health from a “neutral” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research note on Monday, January 14th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $81.84.
In other news, insider Lewis Levy sold 640 shares of the business’s stock in a transaction dated Monday, December 17th. The stock was sold at an average price of $50.00, for a total transaction of $32,000.00. Following the completion of the transaction, the insider now owns 640 shares of the company’s stock, valued at $32,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adam C. Vandervoort sold 5,500 shares of the business’s stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $53.80, for a total value of $295,900.00. Following the transaction, the insider now directly owns 2,934 shares of the company’s stock, valued at approximately $157,849.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 127,493 shares of company stock worth $7,734,360. Company insiders own 3.95% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Enlightenment Research LLC purchased a new position in shares of Teladoc Health during the fourth quarter worth about $25,000. Nikko Asset Management Americas Inc. purchased a new stake in Teladoc Health in the fourth quarter worth approximately $25,000. Ffcm LLC purchased a new stake in Teladoc Health in the fourth quarter worth approximately $32,000. Parkside Financial Bank & Trust boosted its stake in Teladoc Health by 1,455.0% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,244 shares of the health services provider’s stock worth $62,000 after buying an additional 1,164 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in Teladoc Health in the fourth quarter worth approximately $83,000.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Read More: What is the Gross Domestic Product (GDP)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.